Fortress Biotech, Inc.
FBIO
$1.64
-$0.02-1.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -12.80% | 1.78% | 1.59% | 2.53% | -11.05% |
| Total Other Revenue | -94.88% | 3,268.79% | 5,008.75% | 8,670.72% | 629.96% |
| Total Revenue | -31.76% | 31.51% | 31.68% | 32.48% | 11.58% |
| Cost of Revenue | -39.69% | -47.31% | -43.33% | -31.21% | -20.61% |
| Gross Profit | 54.78% | 99.55% | 88.99% | 71.15% | 48.73% |
| SG&A Expenses | -4.45% | -22.69% | -28.95% | -28.64% | -22.72% |
| Depreciation & Amortization | -9.11% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -27.20% | -36.22% | -36.28% | -28.82% | -20.11% |
| Operating Income | 24.37% | 57.94% | 56.47% | 47.13% | 32.09% |
| Income Before Tax | 21.60% | 32.38% | 52.32% | 37.25% | 28.03% |
| Income Tax Expenses | -22.12% | -24.07% | 15.81% | 15.81% | 15.81% |
| Earnings from Continuing Operations | 21.60% | 32.36% | 52.19% | 37.14% | 27.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -19.95% | -28.08% | -48.24% | -34.36% | -26.56% |
| Net Income | 24.14% | 38.05% | 57.51% | 40.97% | 29.96% |
| EBIT | 24.37% | 57.94% | 56.47% | 47.13% | 32.09% |
| EBITDA | 24.32% | 58.82% | 57.21% | 47.75% | 32.60% |
| EPS Basic | 68.19% | 72.17% | 76.58% | 59.12% | 42.87% |
| Normalized Basic EPS | 146.44% | 151.26% | 68.86% | 84.38% | 48.75% |
| EPS Diluted | 68.19% | 72.17% | 76.58% | 59.12% | 42.87% |
| Normalized Diluted EPS | 146.44% | 151.26% | 68.86% | 84.38% | 48.75% |
| Average Basic Shares Outstanding | 150.40% | 137.88% | 105.24% | 73.11% | 36.89% |
| Average Diluted Shares Outstanding | 150.40% | 137.88% | 105.24% | 73.11% | 36.89% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 0.34% | -0.21% | -1.35% | -0.69% | -0.43% |